Iroko buys Canadian antibiotic rights
Philadelphia, USA-based drugmaker Iroko Pharmaceuticals says it has acquired Canadian rights to the oral antibiotic Vancocin (vancomycin HCl) from Eli Lilly. The drug is indicated for the treatment of bacterial infections of the lower digestive tract, including those caused by the "superbug" Clostridium difficile. The deal, financial terms of which were not provided, follows on from Iroko's purchase of rights to Merck & Co's products Aldomet (methyldopa) and Indocin (indomethacin), which was announced earlier this year (Marketletter April 2).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze